Randomized phase II evaluation of fludarabine (RdA) and 2-chloredeossiadenosine (CdA) in the treatment of relapsed/refractory low-grade non-Hodgkin's lymphoma (NHL) and CLL.

被引：0
|
作者：
Tondini, C
Balzarotti, M
Rampinelli, I
Luoni, M
DePaoli, A
Valagussa, P
Santoro, A
Bajetta, E
Bonadonna, G
Bregni, M
机构：
[1] IST NAZL TUMORI,I-20133 MILAN,ITALY
[2] OSPED CIVILE LEGNARO,LEGNARO,ITALY
来源：
BLOOD | 1997年 / 90卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1532 / 1532
页数：1
相关论文
共 50 条
  • [1] Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: A phase II randomized study
    Tondini, C
    Balzarotti, M
    Rampinelli, I
    Valagussa, P
    Luoni, M
    De Paoli, A
    Santoro, A
    Bonadonna, G
    ANNALS OF ONCOLOGY, 2000, 11 (02) : 231 - 233
  • [2] Fludarabine, mitoxantrone and dexametasone in the treatment of relapsed and refractory low-grade non-Hodgkin lymphoma.
    Sawczuk-Chabin, J
    Kalinka, E
    Centkowski, P
    Budziszewska, K
    Ceglarek, B
    Najda, J
    Blasinska-Morawiec, M
    Sulek, K
    Holowiecki, J
    Konopka, L
    Warzocha, K
    BLOOD, 2005, 106 (11) : 265B - 265B
  • [3] Daunoxome in the treatment of relapsed/refractory low grade and intermediate grade non-Hodgkin's lymphoma (NHL)
    Tulpule, A
    Rarick, MU
    Kolitz, J
    Bernstein, J
    HarveyBuchanan, L
    Espina, BM
    Trader, G
    Mukwaya, G
    Onetto, N
    Gill, PS
    Levine, AM
    BLOOD, 1997, 90 (10) : 846 - 846
  • [4] Phase II clinical evaluation of bryostatin-1 in patients with relapsed low grade non-Hodgkin's lymphoma (LGL) and CLL.
    Varterasian, M
    Mohammad, R
    Shurafa, M
    Eilender, D
    Murgo, A
    Hulburd, K
    Rodriguez, D
    Pemberton, P
    LaGrone, F
    Manica, B
    Spadoni, V
    Al-Katib, A
    BLOOD, 1998, 92 (10) : 412A - 412A
  • [5] A phase II study of gemcitabine in patients with relapsed or refractory low-grade non-hodgkin lymphoma
    Larson, BJG
    Waples, JM
    Pusateri, A
    Mendenhall, NP
    Lynch, JW
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2005, 28 (02): : 165 - 168
  • [6] Phase II study of fludarabine and cyclophosphamide in the treatment of relapsed low grade non-Hodgkin's lymphoma.
    Lucie, NP
    Dunlop, DJ
    Soukop, M
    McKay, PJ
    Stark, AN
    Anderson, SM
    Paul, J
    BLOOD, 2001, 98 (11) : 606A - 607A
  • [7] Phase II trial of Doxil® in patients with refractory/relapsed low-grade non-Hodgkin's lymphoma.
    Di Bella, NJ
    Khan, MM
    Dakhil, SR
    Logie, KW
    Marsland, TA
    Simon, SR
    Weinstein, RE
    BLOOD, 2000, 96 (11) : 236B - 236B
  • [8] Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma
    Santini, G
    Nati, S
    Spriano, M
    Gallamini, A
    Pierluigi, D
    Congiu, AM
    Truini, M
    Rubagotti, A
    Chisesi, T
    Vimercati, R
    Rossi, E
    Sertoli, MR
    Mattei, D
    Marino, G
    Gobbi, M
    HAEMATOLOGICA, 2001, 86 (03) : 282 - 286
  • [9] Fludarabine (FLU) in combination: An effective therapy for relapsed or refractory low-grade non-Hodgkin's lymphoma (LGL)
    Santini, G
    Nati, S
    Spriano, M
    Congiu, AM
    Marino, G
    Rossi, E
    Vimercati, R
    Pierluigi, D
    Clavio, M
    Gobbi, M
    Damasio, E
    EXPERIMENTAL HEMATOLOGY, 1999, 27 (07) : 80 - 80
  • [10] Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma
    Dumontet, C
    Morschhauser, F
    Solal-Celigny, P
    Bouafia, F
    Bourgeois, E
    Thieblemont, C
    Leleu, X
    Hequet, O
    Salles, G
    Coiffier, B
    BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (03) : 772 - 778
12345